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Abstract
Background: Urinary mercury concentrations are used in research exploring mercury exposure. Some theorists have
proposed that autism is caused by mercury toxicity. We set out to test whether mercury concentrations in the urine of
children with autism were significantly increased or decreased compared to controls or siblings.
Methods: Blinded cohort analyses were carried out on the urine of 56 children with autism spectrum disorders (ASD)
compared to their siblings (n= 42) and a control sample of children without ASD in mainstream (n= 121) and special schools
(n= 34).
Results: There were no statistically significant differences in creatinine levels, in uncorrected urinary mercury levels or in
levels of mercury corrected for creatinine, whether or not the analysis is controlled for age, gender and amalgam fillings.
Conclusions: This study lends no support for the hypothesis of differences in urinary mercury excretion in children with
autism compared to other groups. Some of the results, however, do suggest further research in the area may be warranted
to replicate this in a larger group and with clear measurement of potential confounding factors.
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Introduction
Some authors have been concerned that mercury-based
preservatives in certain vaccinations [1], mercury in maternal
dental fillings [2], or childhood mercury exposure from a range of
environmental sources [3] may affect the brains of children,
leading to autism in some individuals. This has arisen in the
context of studies of neurological damage from environmental
mercury or methylmercury poisoning [4], [5], and speculation as
to the effect of ethylmercury in thimerosal-based vaccines [6].
Hypotheses such as these have generated much parental anxiety
[7], have been implicated in reductions in childhood vaccination
rates [8] and have been subsequently associated with increases in
cases of measles and mumps, with significant long term
implications for individuals [9]. As such, direct and rigorous
testing of such hypotheses is vital not only for understanding
autism, but for wider public health reasons.
Developmental problems associated with environmental mer-
cury exposure are well documented. In a study of 63 infants in
Japan with congenital mercury poisoning a range of reported
problems were observed, including significant learning disabilities,
limb deformities, cerebellar ataxia [4], hypersalivation, chorea and
microcephaly [10]. Cerebral pathological changes showed demy-
elination of the pyramidal tracts, hypoplasia of the corpus
callosum, widespread disturbance of brain growth and neuronal
migration, neuronal and generalised cortical atrophy and
underdevelopment of the granula layer of the cerebellum [5]. A
further study in the Philippines where mercury is used in the gold
mining industry found that prenatal exposure to mercury led to
increased rates of global developmental delay [11].
It is well established that environmental mercury in high doses is
very toxic [12], [13]. In Iraq in the 1970s, over 450 people died
and over 5000 suffered poisoning following the use of methylmer-
cury fungicide to treat grain [14], [15] and in Japan, industrial
waste containing mercury, poisoned over 2000 people [4]. There
have been several reviews examining mercury poisoning from
follow up studies in Japan, Iraq, Peru, the Philippines, the Faroe
Islands and the Seychelles [12], [13], [16], [17]. but, none of these
have to date presented an association specifically with autistic
symptomatology.
Much lower exposure to mercury than seen in these studies
occurs in most societies, with one route being the use of mercury in
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amalgam fillings. In a study in Portugal over 500 children aged 8–
10 were randomised to receive either amalgam fillings or
composite fillings [18]. The amalgam group showed higher levels
of creatinine-corrected urinary mercury levels at follow-up, but no
differences in a range of neurobehavioural measures between the
two groups over seven years follow-up. A similar study in Boston,
USA followed children up for five years and came to similar
conclusions [19], where children who were randomised to receive
amalgam fillings were not statistically different on psychometric
testing (including IQ and memory) to those receiving composite
fillings.
The fear that mercury causes autism came from speculation that
the use of thimerosal in certain vaccinations may have caused rates
of autism diagnoses to rise [1], [6]. This was proposed despite the
fact that the mercury compound it contains, ethylmercury cannot
easily pass through the blood-brain barrier, as methlymercury can
and is associated with few central nervous system problems in
environmental health research [20]. Although one research group
has published several studies linking autism rates and mercury/
thimerosal [21], [22] a number of high-quality cohort and
ecological studies have found no evidence to support their claims
[7], [23]. Most notably, increasing rates of autism have been
observed in three countries even after thimerosal was removed
from their vaccination programme [24], [25].
Despite this, some authors have continued to posit mercury-
related abnormalities in the development of autism. It has been
hypothesised that children with autism may have a problem
excreting mercury from the body [26] following evidence of
reported low concentrations of mercury in the hair of 90 children
with autism compared to 45 healthy controls [27]. This hypothesis
exists despite the fact that other studies using hair mineral analysis
have found no differences in mercury concentrations [28]–[30]
and one study found increased concentrations in hair, along with
other potentially hazardous metals [31].
Another excretion route is urine; if mercury excretion were
impaired in ASD children, this should also be evident in their
urinary levels of mercury. Whilst urine studies exploring foetal
exposure in mothers who eat large amounts of mercury in fish
have found no neurocognitive risk to the children of mothers
eating on average 12 fish meals per week [32],[33], higher
maternal mercury consumption (eating regular amounts of whale
meat), has been associated with a range of subtle neurodevelop-
mental effects in language, attention and memory in their infants
[34].
Studies that have looked specifically at the urine of children with
autism have produced mixed results. Bradstreet and colleagues
[35] reported higher levels of mercury in the urine of 221 children
with ASD compared to controls following oral chelation treatment
(to bind mercury and force excretion), which they argued was
consistent with Holmes and colleagues’ [27] suggestions of poor
excretion and subsequent build-up of mercury levels in children
with autism. Another study by the same group [36] reported
increased urinary porphyrin levels related to heavy metal body-
burden in a sample of ASD children. In contrast, a study by Soden
and colleagues [37] found no evidence of increased levels of
urinary mercury or any other heavy metals in ASD participants
and controls following chelation.
None of the above studies directly measured urinary levels of
mercury in children who had no form of chelation treatment.
Furthermore, the Geier/Bradstreet group has only used very small
control samples (n=18, 14 & 5 respectively), perhaps because of
the use of chelation, which is potentially harmful for children [38].
As such, there is a lack of high-quality evidence on ordinary
urinary mercury levels in ASD children, at a time - with parental
concerns about mercury persisting [39] - when clear and unbiased
data on the issue is needed.
We set out to do a blinded study to compare urine
concentrations of mercury between groups of children with autism
spectrum disorders and controls. Unlike other studies of urinary
mercury in autism we examined ordinary, non-treatment levels of
mercury and compared them to three different control groups;
mainstream schoolchildren (n=115), children from special schools
(n=28) and ASD siblings (n=40). To account for differing levels of
mercury exposure across groups, the number of current amalgam
fillings was recorded. Urine concentration was controlled for by
correcting for creatinine. Given some authors views that heavy
metals more broadly might be implicated or face excretion
difficulties [36], [40], we set out to do some pilot work in this area
by doing preliminary analysis on other easily measurable heavy
metals in the urine. We did this in part to check whether any
hypothesised problems were specific or occurred across a group of
heavy metals.
Methods
Samples of urine were collected from children with autism
spectrum disorders (ASDs), ASD siblings, mainstream control
children and special school control children. A special school
mainly educates children with learning disabilities in the first
percentile range. The sample were subsequently frozen at 280uC.
Diagnoses of Childhood Autism, Atypical Autism or Asperger
Syndrome were made using Research Diagnostic Criteria (RDC)
from the World Health Organisation International Classification
of Diseases system version 10 [41] through a multidisciplinary
panel that considers all local ASD assessments. A local Autism
Spectrum Disorders Forum is a mutlidsciplinary group that
assesses and diagnoses all local children. All families on their
database were sent information about the research from their
clinician and those giving informed consent were recruited into the
study. The protocol requires the RDC to be established across
home, school and clinic. Where there was uncertainty the Autism
Diagnostic Inventory-Revised (ADI-R) [42] and the Autism
Diagnostic Observation Schedule-Generic (ADOS-G) [43] were
used. Both are instruments that enhance and support ICD-10
diagnosis. For controls, healthy children without autism (or any
previous assessments for ASD) from both special schools and
mainstream schools were recruited in cohorts from schools
supportive of the research.
Ethical and governance approval was granted by local health
ethics and R&D Committees in York. Exclusion criteria included
any known metabolic or neurological disorder. Children were
excluded from the control group if they had received an
assessment for an autism spectrum disorder or where concerns
had been raised by the teacher that the child might be on the
autism spectrum. Where capacity to provide written consent was
reduced then those with parental responsibility provided written
consent on their child’s behalf with the child or young person also
giving their assent.
Morning samples were collected in sterile plastic pots, sealed
and then placed in a sealed plastic wrapper until collection. No
sulfamic acid or surfactant was used. The urine samples were
blinded with code numbers and delivered via one of several points
of collection to a local Department of Clinical Biochemistry within
24 hours. Creatinine concentrations were determined and aliquots
were separated and frozen at 220uC. Analysis of urine was
calculated at the Food and Environment Agency at Sand Hutton
and the Health and Safety Laboratory in Sheffield, as described
below.
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Technical methodology
The analytical laboratories remained blinded to identity or
diagnosis throughout.
Central Science Laboratory (Food and Environment
Research Agency - Fer). Fer’s role in the project was to
provide multi-element data. A random subsample (mainstream
n=24, ASD n=11, special school n = 9) was selected by a
laboratory technician blinded to diagnosis or any identifying
information using randomised numbers. These urines were
additionally tested for other heavy metals. Fer performed an
initial screen of 25 elements which, after QA/QC assessment, was
reduced to 10, i.e., lithium, vanadium, manganese, cobalt, copper,
cadmium, antimony, barium, mercury and lead. Using this, the
Limits of Distinction (LOD) were calculated and were all
satisfactory except the LOD achievable for mercury, which was
0.9 mg/l, and so all samples were then sent to the Health and
Safety Laboratory (HSL) for analysis of this specific element given
lower available LODs. The Limit of Detection (LOD) describes
the lowest level a target substance can be reliably detected.
Measurement of the other nine elements was by Inductively
Coupled Plasma Mass Spectrometry*. All aspects of the method
were performed to UKAS acceptable criteria. Fer is a regular
successful participant in the relevant Series of FAPAS (proficiency
testing scheme).
Health and Safety Laboratory Method for mercury
analysis. Mercury was determined in urine samples using
Inductively Coupled Plasma Mass Spectrometry (ICP-MS)
Thermo Fisher Scientific X7, Series 1 (Hemel Hempstead, UK).
The urine samples were defrosted at room temperature and rolled
to mix. The urine samples were then diluted 1 in 10 (very small
samples were diluted 1 in 5) with 5% nitric acid solution,
containing 10 mg/L platinum as an internal standard and 1 mg/L
gold as a stabiliser for the mercury. External quality control (EQC)
samples (Bio-Rad Level 1 Lypocheck Urine) and a 5 mg/L
calibration standard check were analysed at the start and end of
analysis and after every ten samples. The aqueous calibration
standards were in the range 0–100 mg/L. Any sample outside the
calibration range would be repeated. The ICP-MS was operated
in normal mode with direct nebulisation and a dedicated mercury
rinse solution was aspirated containing 1 mg/L gold and 5% nitric
acid.
The results for the EQC for 53 samples was 40.564.6 mg/L
(expected range for BR 69091 38–58 mg/L). The stability of the
5 mg/L check standard was 560.5 mg/L. The method is UKAS
accredited and acquires successful participation in both the UK
TEQAS and German G-EQUAS quality assurance schemes.
In this study the LOD for mercury using a volume of 1 millilitre
was 0.35 nmol/L (0.07 mg/l). The LODs for elements other than
mercury were all well below the levels being found.
Analysis was performed to see if there was any relationship
between mercury levels and diagnostic group. This test was
performed twice: i) without creatinine correction and ii) with
creatinine correction. Creatinine ratios were calculated to correct
for variations in urinary mercury caused by body mass and urine
concentration.
Some levels of mercury (28) in urine were below the limit of
detection (LOD). In order not to lose valuable information in the
analysis, we have analysed the data treating values below the
LOD in two ways, firstly treating it as zero and secondly using the
mercury LOD threshold value (0.35 nmol/L). This covers the
spread of possible values below the limit of detection (i.e. the
amount could be anything (from zero to 0.35 nmol/L). The
statistical analysis therefore covers this range of possible options.
In addition, data about the number of current in situ amalgam
fillings was collected systematically from all participants’ dental
records.
Statistical analysis
The power calculation was based on the study by Holmes and
colleagues [27], who found that mercury levels (reported as parts
per million) in first baby haircut was 0.47 (60.28) for Autistic
and 3.63 (63.56) for controls. To detect a difference of 3 between
the Autistic group in this study and the control groups, 33
patients are required per group, based on 80% power and 5%
significance.
The four groups were compared using Kruskall Wallis tests for
continuous data and Chi-Square for categorical data. A p-value of
,0.05 was considered to indicate statistical significance. To adjust
of the effects of age, gender and number of fillings multiple
regression was undertaken. All analyses were performed on SPSS
(version 18). Kruskal-Wallis tests were utilised instead of
parametric equivalents due to skew in the raw data.
Results
Included in the study were 251 children: 54 children on the
autism spectrum, 155 children without autism (121 were currently
attending mainstream school and 34 children were attending a
special school), and 42 children who were the siblings of those with
ASD.
There was a significant difference between the groups for age
(F(3) = 20.726, p,0.001), and gender (Chi(3) = 15.900, p = 0.001).
The number of fillings was slightly lower in ASD children
(Table 1), although this was not statistically significant (KW
(3) = 3.907, p=0.272), even after grouping participants into those
with or without fillings (Chi(3) = 3.893, p = 0.273).
Table 1 gives data on urine mercury level for the ASD and
control groups. Mercury levels were attained for 230 of the 251
children (92%). Of these 28 results that were below LOD were
replaced by either 0.35 or zero. (as described above).
There were no significant differences between the four groups in
uncorrected mercury level regardless of how the values below the
LODs were treated [mercury level with blanks given zero
(KW(3) = 5.135, p = 0.162), or mercury level with blanks given
0.35 (KW(3) = 5.223, p = 0.156]. There was no difference between
the groups and creatinine levels (KW(3) = 1.734, p = 0.630).
Table 1 and Figure 1 show the data for the urine mercury
corrected for creatinine. There were no significant differences
between the four groups regardless of how the values below the
LODs were treated (mercury level with blanks given zero
(KW(3) = 6.889, p= 0.076) or mercury level with blanks given
0.35 (KW(3) = 7.450, p = 0.059)). Even after removing outliers
with extreme values (children with values more than 3 box lengths
from the upper or lower edge of the box. (The box length is the
interquartile range) there were no significant differences between
groups (mercury level with blanks given zero (KW(3) = 5.738,
p = 0.125) or mercury level with blanks given 0.35 (KW(3) = 6.333,
p = 0.096)).
After adjusting for age, gender and number of fillings, there was
still no statistically significant difference between the groups
(mercury level with blanks given zero: F (3) = 2.587, p = 0.056;
mercury level with blanks given 0.35: F (3) = 2.570, p = 0.056),
even after removing extreme values (mercury level with blanks
given zero: F (3) = 0.897, p= 0.444; mercury level with blanks
given 0.35: F (3) = 0.867, p = 0.459).
Tests of other heavy metals find no differences between groups.
This includes lithium (p= 0.344), vanadium (p= 0.951), manga-
nese (p = 0.613),cobalt (p = 0.392, copper (p = 0.391), cadmium
Urinary Mercury in Autism Spectrum Disorders
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(p = 0.586), antinomy (p = 0.216), barium (p= 0.328) and lead
(p = 0.203)*.
Discussion
The hypothesis that mercury poisoning (either through
increased exposure or reduced excretion) may cause autism is a
cause of anxiety to many parents. It may prompt them to change
vaccination behaviour and in some rare cases to use oral chelating
agents, both of which pose a risk to the child [38].
The widespread but much lower dose exposure of children to
ethylmercury in some vaccinations containing thimerosal has been
studied epidemiologically [44] and to date has not been shown to
be associated with autism [45]. Blood levels of mercury after
vaccination also appear to be very low [46]. Most tellingly, rates of
diagnosis for autism continued to rise, after thimerosal use in
paediatric vaccines in the developed world was discontinued in
2001 [47].
We found no statistically significant differences in urinary
mercury corrected for creatinine, between the groups compared to
the control groups, mainstream children and siblings. The other
heavy metals showed no differences that would have encouraged
us to test the whole group for these elements, or to suggest broader
heavy metal metabolism problems.
We interpret our findings with caution. The results appear to be
influenced strongly by a small number of extreme values in the
ASD and special school group but not the other two groups (see
Figure 1). There is no significant difference between groups when
the extreme values are removed The ASD or LD groups do not
appear to have more or less amalgam fillings, although it is known
that amalgam fillings affect urinary mercury content. A lower
creatinine in the ASD group (not statistically significant) raises the
mercury to creatinine ratio in this subgroup, but not to statistically
significant levels. Since creatinine is dependent on age, race, body
mass index, fat free mass [48] and glutathione metabolism/
genetics [49] future studies should include measures of these
variables for analysis.
This study makes no comparisons of brain mercury levels
between the two groups. The finding by Holmes and colleagues
[27] that mercury levels in the hair were lower are difficult to
reconcile with our results but it could be that their ASD children
had lower exposure to amalgam fillings or (possible though
unlikely) impaired selective hair excretion in the absence of
impaired urinary excretion.
The present study has limitations that must be considered. The
sample size is relatively small. Given the KW and P scores there is
a possibility that there is a type II error with inadequate power.
Our data can be used to calculate numbers needed for a future
adequately powered study. Whilst collection of 24-hour urines may
have improved accuracy, such samples are very difficult to collect
in children with learning disability and autism and research shows
good correlations between spot urines and 24-hour collections
[50].There was variability of urine collection rates between
participant groups. The sibling group and mainstream children
provided higher sample rates than those for special school children
and ASD children. These groups had slightly lower rates mainly
Table 1. Urinary mercury, creatinine and numbers of amalgam dental fillings.
ASD Special School Mainstream School Sibling
Urinary mercury levels
N 54 34 121 42
Age (M/SD) 9.6 (3.6) 12.6 (3.5) 8.8 (2.4) 12.1 (3.6)
Sex (N/% Male) 42/53 (79%) 18/34 (53%) 65/119 (55%) 17/42 (41%)
Returned urines from consented children 47 (87%) 28 (82%) 115 (95%) 40 (95%)
Number below LOD of 0.35 2 (4%) 3 (11%) 15 (13%) 8 (20%)
Number of amalgam dental fillings N 41 28 98 29
No fillings 36 (88%) 22 (79%) 72 (74%) 24 (83%)
1 or more 5 (12%) 6 (21%) 26 (26%) 5 (17%)
M (SD) 0.4 (1.3) 0.5 (1.3) 0.7 (1.4) 0.3 (0.8)
Mercury M (SD) nmol/l N 47 28 115 40
Values below LOD treated as 0.35 6.61 (6.95) 6.43 (5.80) 6.23 (7.14) 4.38 (4.34)
M (SD) Median (1QR) 5.20 (2.80, 6.90) 4.65 (2.35, 9.20) 4.00 (1.80, 7.10) 3.35 (0.50. 6.45)
Values below LOD treated as 0 6.60 (6.96) 6.39 (5.84) 6.18 (7.18) 4.30 (4.42)
M (SD) Median (1QR) 5.20 (2.80, 6.90) 4.65 (2.35, 9.20) 4.00 (1.80, 7.10) 3.35 (0.50, 6.45)
Creatinine 10.35 (5.27) 11.11 (5.15) 11.22 (4.62) 11.75 (4.86)
M (SD) Median (1QR) 10.05 (6.60, 14.60) 10.40 (7.50, 14.30) 10.20 (8.00, 13.30) 10.60 (8.00, 15.10)
Mercury nmol/l/Creatinine mmol/l..N 47 28 115 40
Mercury nmol/l (Values below LOD treated as 0.35)/
Creatinine mmol/l
0.94 (1.35) 0.90 (1.48) 0.58 (0.57) 0.52 (0.62)
M (SD) Median (1QR) 0.52 (0.32, 0.93) 0.42 (0.21, 0.94) 0.38 (0.19, 0.76) 0.33 (0.04, 0.58)
Mercury nmol/l (Values below LOD treated as 0.35)/
Creatinine mmol/l
0.94 (1.35) 0.89 (1.49) 0.57 (0.58) 0.52 (0.63)
M (SD) Median (1QR) 0.52 (0.32, 0.93) 0.42 (0.21, 0.94) 0.38 (0.19, 0.76) 0.33 (0.03, 0.58)
No mercury samples fell outside the calibration range.
doi:10.1371/journal.pone.0029547.t001
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because of communication problems and difficulty obtaining co-
operation. However, overall sample rates were good for a study of
this kind, and a notable strength of the study is its large sample of
controls in comparison to previous urinary studies [35], [36]. This
field needs further high quality, large sample work that collects
good data on age, diet, BMI and amalgam fillings.
This study does not lend support for widespread mercury
metabolism problems in autism, but given small numbers of
outliers it does suggest further research is warranted to better
understand whether a subgroup with autism or learning disabilities
have mercury poisoning or excretion difficulties. Recent research
has however found no association between autism and genes
polymorphisms responsible for controlling the transport and
response to body mercury [51]. Given that research shows that
environmental mercury is toxic to humans, avoiding mercury
exposure remains intuitively sensible. However, a clear causal link
to autistic spectrum disorders remains unlikely.
*Further details are available from the corresponding author.
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